BRIEF—EMA's PRAC held public hearing on quinolone and fluoroquinolone antibiotics

At its June meeting, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) discussed two ongoing safety reviews.

As part of a safety review investigating the persistence of serious side effects with quinolone and fluoroquinolone antibiotics mainly affecting muscles, joints and the nervous system, the PRAC held a public hearing to listen to the views and experiences of European citizens.

The aim of the hearing was to explore which further measures could ensure that these antibiotics are used as safely as possible.

The insights from participants will complement the available scientific evidence, will enrich the PRAC’s deliberations and will be used to finalise its assessment.

A summary report will be published on EMA’s website shortly.

Ongoing safety reviews are shown in the table below. The Committee did not start or conclude a referral.

Ongoing referrals